Table 1 Demographics and baseline characteristics in 10, 25 and 50 µg PvDBPII vaccine and 20 µg Hepatitis B vaccine groups–ITT Population

From: Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial

Parameter

Statistics/category

PvDBPII (10 µg) N = 9

PvDBPII (25 µg) N = 9

PvDBPII (50 µg) N = 9

Hepatitis B (20 µg) N = 9

Age (in years)

N

9

9

9

9

Mean ± SEM

29.78 ± 2.09

34.56 ± 1.85

27.56 ± 1.74

34.67 ± 2.12

Median

28

36

30

35

(Min, Max)

(22.00, 42.00)

(25.00, 41.00)

(18.00, 33.00)

(26.00, 45.00)

Range

20

16

15

19

*p-Value

0.051

Weight (kg)

N

9

9

9

9

Mean ± SEM

62.87 ± 2.77

67.84 ± 2.26

66.94 ± 2.36

68.61 ± 2.03

Median

63

70

66.2

66.1

(Min, Max)

(51.00, 74.00)

(56.00, 76.00)

(57.30, 77.00)

(61.00, 79.30)

Range

23

20

19.7

18.3

*p-Value

0.442

Height (cm)

N

9

9

9

9

Mean ± SEM

166.67 ± 1.76

170.11 ± 1.97

169.67 ± 1.77

168.22 ± 2.67

Median

167

171

169

166

(Min, Max)

(158.00, 175.00)

(161.00, 179.00)

(159.00, 176.00)

(159.00, 183.00)

Range

17

18

17

24

*p-Value

0.566

  1. Max maximum, Min minimum
  2. N = total number of subjects randomized
  3. *p-Value: between study group comparison is performed using Kruskal–Wallis test